ClinVar Miner

Submissions for variant NM_000350.3(ABCA4):c.4469G>A (p.Cys1490Tyr) (rs61751402)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000085641 SCV000229300 pathogenic not provided 2016-03-31 criteria provided, single submitter clinical testing
Institute of Human Genetics, Univ. Regensburg,Univ. Regensburg RCV000177442 SCV000281893 pathogenic Stargardt disease 1 2016-01-01 criteria provided, single submitter clinical testing
GeneDx RCV000085641 SCV000511898 pathogenic not provided 2016-02-26 criteria provided, single submitter clinical testing The C1490Y pathogenic variant has previously been reported in association with Stargardt disease and cone-rod dystrophy (Lewis et al., 1999; Stenirri et al., 2004; Wiszniewski et al., 2005; Valverde et al., 2006). In vitro functional studies demonstrated that the presence of the C1490Y variant resulted in reduced basal and retinal ATPase activities relative to wild-type (Sun et al., 2000; Wiszniewski et al., 2005). In vivo functional studies further demonstrated that the presence of the C1490Y variant results in impaired protein folding and localization (Wiszniewski et al., 2005). The C1490Y variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function.
Illumina Clinical Services Laboratory,Illumina RCV000779003 SCV000915444 pathogenic ABCA4-Related Disorders 2018-08-14 criteria provided, single submitter clinical testing Across a selection of the available literature, the ABCA4 c.4469G>A (p.Cys1490Tyr) missense variant has been identified in one individual with cone rod dystrophy in a compound heterozygous state and in eight individuals with Stargardt disease, including in one in a homozygous state, in six in a compound heterozygous state, and in one in a heterozygous state. The individual who was heterozygous for the p.Cys1490Tyr variant also carried two additional variants for which zygosity was not determined (Lewis et al. 1999; Stenirri et al. 2004; Wiszniewski et al. 2005). The p.Cys1490Tyr variant has not been seen in the literature in association with autosomal recessive retinitis pigmentosa or autosomal dominant macular degeneration. The p.Cys1490Tyr variant was absent from 220 controls and is reported at a frequency of 0.00038 in the European (non-Finnish) population of the Exome Aggregation Consortium. Expression of the p.Cys1490Tyr variant protein in HEK293 cells revealed protein levels comparable to wild type but somewhat reduced basal ATPase activity (Sun et al. 2000). Expression in COS7 cells revealed that variant protein resulted in the rate of ATP hydrolysis being decreased to 21.4% of wild type. Expression in transgenic frogs demonstrated that the p.Cys1490Tyr variant protein was mislocalized (Wiszniewski et al. 2005). Based on the collective evidence, the p.Cys1490Tyr variant is classified as pathogenic for ABCA4-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Invitae RCV000085641 SCV001223094 pathogenic not provided 2019-12-02 criteria provided, single submitter clinical testing This sequence change replaces cysteine with tyrosine at codon 1490 of the ABCA4 protein (p.Cys1490Tyr). The cysteine residue is highly conserved and there is a large physicochemical difference between cysteine and tyrosine. This variant is present in population databases (rs61751402, ExAC 0.04%). This variant has been observed in individual(s) with Stargardt disease and retinitis pigmentosa (PMID: 23695285, 25082885, 25472526, 24713488, 28041643). In at least one individual the data is consistent with the variant being in trans (on the opposite chromosome) from a pathogenic variant. This variant has been suggested to be a founder mutation in individuals of South African descent (PMID: 23695285). ClinVar contains an entry for this variant (Variation ID: 99288). This variant has been reported to affect ABCA4 protein function (PMID:16103129). For these reasons, this variant has been classified as Pathogenic.
Blueprint Genetics RCV000210300 SCV001240421 pathogenic Retinal dystrophy 2019-07-16 criteria provided, single submitter clinical testing
CeGaT Praxis fuer Humangenetik Tuebingen RCV000085641 SCV001248242 pathogenic not provided 2020-01-01 criteria provided, single submitter clinical testing
Retina International RCV000085641 SCV000117780 not provided not provided no assertion provided not provided
Centre for Genomic Medicine, Manchester,Central Manchester University Hospitals RCV000210300 SCV000259105 pathogenic Retinal dystrophy 2015-01-30 no assertion criteria provided clinical testing
NIHR Bioresource Rare Diseases, University of Cambridge RCV000177442 SCV000598975 likely pathogenic Stargardt disease 1 2015-01-01 no assertion criteria provided research
GenomeConnect, ClinGen RCV000177442 SCV000607272 not provided Stargardt disease 1 no assertion provided phenotyping only GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.
Medical Genetics Laboratory, Kennedy Center,Juliane Marie Center, Rigshospitalet RCV000787763 SCV000926768 pathogenic Macular dystrophy 2018-04-01 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.